Every material Form 8-K Prestige Consumer Healthcare has filed with the SEC since August 08, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prestige Consumer Healthcare reported fiscal second-quarter 2027 revenue of $336.3 million, up 22.7% from a year earlier, with adjusted diluted EPS of $1.13 versus $1.07. The company lowered its fiscal 2027 revenue and adjusted EPS guidance, citing variable Clear Eyes production at its Pillar5 facility, which is expected to reduce product availability and revenue in the second half.
Q2 reported revenue $336.3 million, up 22.7%; organic revenue fell 1.6% excluding acquisitions and foreign currency
Q2 GAAP diluted EPS $0.53 versus $0.86 a year earlier; adjusted diluted EPS $1.13 versus $1.07
Fiscal 2027 revenue outlook lowered to $1,280 million to $1,290 million from $1,290 million to $1,315 million
Fiscal 2027 adjusted diluted EPS outlook lowered to $4.48 to $4.55 from $4.55 to $4.65
On August 10, 2026, Senior Vice President, Operations Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. that he will retire from that role and all other positions he holds with the company, effective August 14, 2026. The filing does not name a successor or describe any separation or compensation terms, so shareholders have limited information on how the operations role will be filled.
Retirement notice given August 10, 2026
Retirement effective August 14, 2026, covering the SVP Operations role and all other positions held
Filing signed by Christine Sacco, Chief Financial Officer and Chief Operating Officer
No successor or separation terms disclosed in the filing
Prestige Consumer Healthcare reported fiscal first-quarter 2027 revenue of $265.7 million, up 6.5%, with organic growth of 3.2%. GAAP diluted EPS fell to $0.61 from $0.95, while adjusted diluted EPS rose to $0.98 from $0.95 after excluding acquisition costs and Pillar5 facility remediation costs. The company raised its fiscal 2027 revenue and EPS outlook, which it said reflects only the addition of the Breathe Right and LaCorium acquisitions.
Q1 revenue $265.7 million, up 6.5% from $249.5 million; organic revenue growth 3.2%
GAAP net income $29.2 million, or $0.61 per diluted share, versus $47.5 million, or $0.95, a year earlier
Adjusted diluted EPS $0.98 versus $0.95; adjustments include $12.8 million of acquisition costs and $7.1 million of Pillar5 remediation costs
Fiscal 2027 revenue outlook raised to $1,290 to $1,315 million from $1,100 to $1,121 million; adjusted diluted EPS outlook raised to $4.55 to $4.65 from $4.42 to $4.51
Prestige Brands, a wholly owned subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due July 15, 2034, under an indenture dated July 15, 2026. The notes are unsecured and guaranteed by the parent company, adding $400 million of long-term debt that shareholders will carry alongside existing obligations.
Principal amount: $400.0 million of 6.250% senior notes due July 15, 2034
Interest payable January 15 and July 15 each year, starting January 15, 2027
Parent company and certain domestic subsidiaries guarantee the notes on an unsecured senior basis
Change of Control triggers an offer to repurchase at 101% of principal; notes may be redeemed from July 15, 2029
Prestige Consumer Healthcare completed its acquisition of LaCorium Health on July 1, 2026, for approximately $150 million in cash, and priced a $400 million offering of 6.25% senior notes due 2034. The company plans to use the notes proceeds, with cash on hand, to redeem its $400 million of 5.125% senior notes due 2028, which changes its interest expense. The filing reports no earnings figures, and the company will report first quarter fiscal 2027 results on August 6, 2026.
Acquisition of LaCorium Health closed July 1, 2026, for approximately $150 million in cash, financed with cash on hand and existing credit facilities
Borrower drew $95.0 million of additional term loans under a July 1, 2026 amendment to its credit agreement
$400 million of 6.25% senior notes due 2034 priced, with closing expected on or about July 15, 2026, to redeem the 5.125% notes due 2028
LaCorium generates approximately $40 million in annual revenue and is expected to generate approximately $12 million in EBITDA once integrated
Prestige Consumer Healthcare completed its $1.045 billion cash purchase of the Breathe Right brand and certain other brands on June 12, 2026, funded by a new term loan and cash on hand. The company also amended its asset-based revolving credit line, raising commitments to $225 million and extending its maturity five years from the closing date, and the filing describes Breathe Right as becoming Prestige's largest brand.
Purchase price of $1.045 billion in cash for Breathe Right and certain other brands from Foundation Consumer Brands, LLC, closed June 12, 2026
New term loan of $1.045 billion priced at Term SOFR plus 2.00%, with quarterly amortization of 0.25% and a possible second draw of up to $95.0 million to help fund the LaCorium Acquisition
ABL revolving line commitments increased to $225 million, with maturity extended five years from the closing date
Prestige Consumer Healthcare agreed to acquire LaCorium Health, an Australian skin care business, for about $150 million in cash, subject to adjustments including indebtedness. The same day it reported fiscal 2026 results showing lower revenue and lower full-year diluted EPS, alongside fiscal 2027 outlook ranges for revenue and adjusted diluted EPS that are above fiscal 2026 levels.
Sale and Purchase Deed for about $150 million in cash; closing expected in the second quarter of fiscal 2027, and either party may terminate before October 1, 2026 for an uncured breach.
Q4 fiscal 2026 revenue was $281.6 million, down 5.0% from $296.5 million; Q4 diluted EPS was $1.13 versus $1.00.
Fiscal 2026 revenue was $1,088.7 million, down 4.3%; diluted EPS was $3.91 versus $4.29, and adjusted diluted EPS was $4.38 versus $4.52.
Fiscal 2027 outlook: revenue of $1,100 million to $1,121 million, adjusted diluted EPS of $4.42 to $4.51, and free cash flow of $250 million or more.
On March 19, 2026, Prestige Consumer Healthcare's subsidiary agreed to acquire Breathe Right and other over-the-counter brands from Foundation for $1.045 billion in cash. The company plans to fund the deal with cash on hand and a new term loan, and expects pro-forma bank-defined net leverage of about 4.0x at closing, with a return below 3.0x targeted in fiscal 2028. Closing is expected in the first half of fiscal 2027 and remains subject to closing conditions, including Hart-Scott-Rodino clearance.
Purchase price is $1.045 billion in cash, or about $900 million net of anticipated tax benefits valued at $150 million.
The acquired portfolio generated about $200 million of revenue and $95 million of EBITDA for the twelve months ended December 31, 2025, a price of about 11.0x EBITDA.
Expected pro-forma bank-defined net leverage is about 4.0x at close, with a target of below 3.0x in fiscal 2028.
Either party may terminate if the deal has not closed by July 20, 2026, subject to exceptions.
Prestige Consumer Healthcare reported fiscal third-quarter 2026 results for the quarter ended December 31, 2025, with revenue of $283.4 million, down 2.4% from a year earlier, and diluted EPS of $0.97 versus $1.22. The company narrowed its fiscal 2026 revenue outlook to approximately $1.1 billion, and its adjusted diluted EPS outlook to approximately $4.54, the low end of its prior range, while keeping free cash flow guidance at $245 million or more.
Q3 revenue of $283.4 million, down from $290.3 million; the company attributed the decline mainly to limited ability to supply demand for Clear Eyes.
Q3 diluted EPS of $0.97 versus $1.22; adjusted diluted EPS of $1.14 versus $1.22 in the prior-year quarter.
Fiscal 2026 revenue outlook narrowed to approximately $1,100 million from $1,100 million to $1,115 million; organic revenue decline now approximately 3.0%.
Repurchased approximately 0.8 million shares for $45.8 million in Q3; Pillar5 Pharma acquisition closed in December.
Prestige Consumer Healthcare reported fiscal second-quarter 2026 revenue of $274.1 million, down 3.4% from a year earlier, mainly due to limited ability to supply Clear Eyes. GAAP diluted EPS fell to $0.86 from $1.09, and adjusted diluted EPS was $1.07 versus $1.09. The company narrowed its fiscal 2026 adjusted EPS outlook to $4.54 to $4.58 from $4.50 to $4.58, while its revenue outlook was unchanged.
Q2 revenue $274.1 million vs. $283.8 million a year earlier; GAAP net income $42.2 million vs. $54.4 million
Q2 diluted EPS $0.86 (GAAP) and $1.07 (adjusted), vs. $1.09 in the prior-year quarter
Fiscal 2026 adjusted diluted EPS outlook $4.54 to $4.58, up from $4.50 to $4.58; revenue outlook $1,100 to $1,115 million unchanged
Repurchased about 1.1 million shares for about $75.0 million in Q2; net debt about $0.9 billion
Prestige Consumer Healthcare reported first-quarter fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million a year earlier, citing limited supply of Clear Eyes. It lowered its fiscal 2026 revenue and diluted EPS outlook and agreed to buy Pillar5 Pharma, its Clear Eyes supplier, for CAD 150 million in cash, subject to adjustments. The lower outlook reflects expected eye care supply shortfalls in the first half, and the acquisition is intended to secure supply, though closing depends on conditions and is expected in the third quarter of fiscal 2026.
Q1 fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million; diluted EPS of $0.95 versus $0.98 a year earlier and $0.90 adjusted
Fiscal 2026 revenue outlook cut to $1,100 million to $1,115 million from $1,140 million to $1,155 million
Fiscal 2026 diluted EPS outlook cut to $4.50 to $4.58 from $4.70 to $4.82; free cash flow outlook of $245 million or more unchanged
Pillar5 Pharma acquisition for CAD 150 million in cash, expected to close in fiscal third quarter 2026 subject to conditions
Prestige Consumer Healthcare reported higher fourth-quarter and full-year fiscal 2025 revenue and diluted earnings per share versus the prior year, and gave initial fiscal 2026 guidance of $1,140 million to $1,155 million in revenue and $4.70 to $4.82 in diluted EPS. The company also recorded a $12.5 million non-cash tradename impairment in the quarter, which it said relates to non-strategic brands, and cited an expected approximately $15 million tariff-related headwind for fiscal 2026.
Q4 fiscal 2025 revenue of $296.5 million rose 7.0% from $277.0 million; diluted EPS was $1.00 versus $0.98
Fiscal 2025 revenue of $1,137.8 million rose 1.1%; diluted EPS was $4.29 versus $4.17, and adjusted diluted EPS was $4.52 versus $4.21
Fiscal 2026 outlook: revenue of $1,140 million to $1,155 million, diluted EPS of $4.70 to $4.82, and free cash flow of $245 million or more
Q4 included a $12.5 million tradename impairment; leverage was 2.4x at March 31, 2025
Prestige Consumer Healthcare reported third-quarter fiscal 2025 revenue of $290.3 million, up 2.7%, with diluted EPS of $1.22 versus $1.06 a year earlier. The company raised its fiscal 2025 adjusted diluted EPS outlook to approximately $4.50 from $4.40 to $4.46, and narrowed its revenue outlook to $1,128 million to $1,132 million. Nine-month revenue declined 0.8%, and third-quarter free cash flow fell, so shareholders gain from higher earnings guidance but see mixed trends in sales and cash flow.
Q3 revenue $290.3 million, up 2.7% from $282.7 million; diluted EPS $1.22 versus $1.06
Nine-month revenue $841.2 million, down 0.8%; non-GAAP adjusted diluted EPS $3.20 versus $3.19
FY2025 adjusted diluted EPS outlook raised to approximately $4.50 from $4.40 to $4.46; revenue outlook $1,128 million to $1,132 million
Q3 non-GAAP free cash flow $63.5 million versus $69.5 million; net debt about $0.9 billion, leverage 2.5x
Prestige Consumer Healthcare said Chief Financial Officer Christine Sacco's role has been expanded to include Chief Operating Officer, effective immediately, and she will oversee the company's supply chain while continuing as CFO. The filing sets out her compensation for the expanded role, including a $700,000 base salary and a $1,575,000 retention RSU award, which shareholders may track in future proxy disclosures.
Sacco, 49, has been CFO since September 2016 and will now serve as COO/CFO, reporting to CEO Ron Lombardi
Annual base salary of $700,000; target annual cash incentive of 75% of base salary
Targeted annual equity award of $1,575,000, split 60% performance stock units and 40% restricted stock units
Time-based RSU retention award with an aggregate value of $1,575,000, cliff vesting four years after grant
Prestige Consumer Healthcare reported fiscal second-quarter 2025 results for the three months ended September 30, 2024. Revenue fell 0.9% to $283.8 million, which the company attributed mainly to limited ability to supply strong demand for Clear Eyes and declines in the Cough & Cold and Analgesic categories, while diluted EPS rose to $1.09 from $1.07 and the company reaffirmed its full-year fiscal 2025 outlook. For shareholders, lower revenue was paired with slightly higher per-share earnings and unchanged guidance.
Q2 revenue of $283.8 million, down 0.9% from $286.3 million a year earlier
Q2 diluted EPS of $1.09 vs. $1.07; net income of $54.4 million vs. $53.6 million
First-half revenue of $550.9 million, down 2.6%; first-half diluted EPS of $2.06 (non-GAAP adjusted $1.98)
Fiscal 2025 outlook reaffirmed: revenue of $1,125 to $1,140 million and adjusted diluted EPS of $4.40 to $4.46
Prestige Consumer Healthcare reported fiscal first quarter 2025 results for the quarter ended June 30, 2024. Revenue fell 4.4% to $267.1 million and diluted EPS was $0.98, versus $1.06 a year earlier, while the company said results were ahead of its own expectations. The company reaffirmed its full-year fiscal 2025 outlook, so shareholders face lower year-over-year earnings with guidance unchanged.
Revenue of $267.1 million, down 4.4% from $279.3 million; organic revenue down 4.3%
Diluted EPS of $0.98 vs. $1.06 a year earlier; adjusted diluted EPS of $0.90
Operating cash flow of $54.8 million vs. $48.1 million; about 0.4 million shares repurchased for $26.0 million
Fiscal 2025 outlook reaffirmed: revenue of $1,125 million to $1,140 million; adjusted diluted EPS of $4.40 to $4.46
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Prestige Consumer Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →